Zobrazeno 1 - 10
of 228
pro vyhledávání: '"H.M Lokhorst"'
Publikováno v:
Haematologica, Vol 92, Iss 12 (2007)
In a prospective phase II study, we evaluated the combination of high dose simvastatin and VAD chemotherapy in patients with refractory or relapsed multiple myeloma. Although treatment was feasible with mild side effects, only 1 of 12 patients achiev
Externí odkaz:
https://doaj.org/article/07943bbf6bc94697a3cf8394500c5256
Autor:
B. Lowenberg, R. Neuwirtova, C. M. Segeren, H. Dohner, H.M Lokhorst, R. Willemze, P. Sonneveld, Stefan Suciu, M. Beksac, H. Gerhartz, P. Weijermans, J van der Lelie, G. Solbu
Publikováno v:
British Journal of Haematology. 115:895-902
Patients with multiple myeloma (MM) refractory to alkylating agents frequently express P-glycoprotein (Pgp), which is associated with the multidrug resistance (MDR) phenotype. We have conducted a randomized phase II/III study of the MDR reversal agen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48c25fea6ff73a859843e5283b7424ec
https://doi.org/10.1046/j.1365-2141.2001.03171.x
https://doi.org/10.1046/j.1365-2141.2001.03171.x
Publikováno v:
JEADV : Journal of the European Academy of Dermatology and Venereology, 21, 986-8
JEADV : Journal of the European Academy of Dermatology and Venereology, 21, 7, pp. 986-8
JEADV : Journal of the European Academy of Dermatology and Venereology, 21, 7, pp. 986-8
Contains fulltext : 51675.pdf (Publisher’s version ) (Closed access)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5f61fae6f774a4c2ee823cceb6b75be
https://doi.org/10.1111/j.1468-3083.2006.02062.x
https://doi.org/10.1111/j.1468-3083.2006.02062.x
Autor:
Pieter Sonneveld, J-P Marie, Brian G.M. Durie, Zittoun R, Stefan Suciu, Kees Nooter, G. Solbu, Bob Löwenberg, H.M Lokhorst
Publikováno v:
The Lancet. 340:255-259
Resistance to chemotherapy in refractory multiple myeloma is frequently associated with expression of multidrug resistance (MDR). In resistant cells, intracellular accumulation of doxorubicin and vincristine does not occur because the MDR- 1 gene pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba51d7e9e083d7ce20c8d53fc2b82bcb
https://doi.org/10.1016/0140-6736(92)92353-h
https://doi.org/10.1016/0140-6736(92)92353-h
Publikováno v:
Amyloid and Amyloidosis ISBN: 9780429125249
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5de2dff5336765a5c567e9903f83446
https://doi.org/10.1201/9781420037494-160
https://doi.org/10.1201/9781420037494-160
Publikováno v:
The Netherlands journal of medicine. 53(6)
We describe a 68-year-old patient presenting with recurrent fever, who eventually turned out to suffer from multiple myeloma. He was treated with Vincristine, Doxorubicin and Dexamethasone combination chemotherapy and intermediate dose Melphalan (70
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6abfe851d18e8f0c2549640c46c0531f
https://pubmed.ncbi.nlm.nih.gov/9883003
https://pubmed.ncbi.nlm.nih.gov/9883003
Autor:
A.W. Dekker, H.M. Lokhorst
Publikováno v:
Cancer treatment reviews. 19(2)
The prognosis for patients with multiple myeloma (MM) has not improved much since the introduction of alkylating agents almost 30 years ago (1, 2). Median survival is approximately 30-36 months and only 50 to 60% of previously untreated patients resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43c346fe4ecbd88d5e1e9f84c4944e09
https://pubmed.ncbi.nlm.nih.gov/7683253
https://pubmed.ncbi.nlm.nih.gov/7683253
Autor:
H.M. Lokhorst
Publikováno v:
Current Diagnostic Pathology. 1:243
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b9e06db1eccd043b01a00279c96dbad
https://doi.org/10.1016/0968-6053(94)90031-0
https://doi.org/10.1016/0968-6053(94)90031-0
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.